Since the therapeutic results in patients with pancreatic carcinoma at present are very modest, it is imperative that new strategies should be developed. The presence of hormone-receptors in pancreatic cancers, the effectiveness of the hormonal manipulations in in vitro and xenograft experiments, the control of the carcinogenesis by hormone-analogs reflect the hormone-sensitivity of this neoplasm and gleam a hope and the possibility of the therapy with hormones. Although the LHRH-and somatostatin analogs proved to be encouraging under numerous experimental conditions by enhancing the process of apoptosis, the results concerning human pancreatic carcinomas are rather disappointing. The inefficacy of the 300-600 μg daily doses of Sandostatin is not surprising, since similar doses have been administered in rodent experiments. For treatment of patients much higher doses seem to be necessary (up to several mg-(s)). The long lasting administration of such quantities is very expensive though. At present somatostatin analogs are also available in sustained-release, microcapsulated forms and the synthesis of new, highly potent peptides is under way. In the near future, hormonal therapy might be a powerful weapon against the pancreatic cancer as an import ant supplementary method along with the surgical resection.
|Number of pages||8|
|Publication status||Published - Jan 1 1995|
ASJC Scopus subject areas